|
Research and Markets Offers Report on Biomarkers: The Future of
Next-Generation Drug R&D
(Wireless News Via Acquire Media NewsEdge)
Research and Markets has announced the addition of the "Biomarkers: The
Future of Next-Generation Drug R&D" report to its offerings.
In a release, Research and Markets noted that report highlights include:
This report analyzes the hot global market for biomarkers and related
assays or tests used in drug R&D. The study reviews this dynamic market
by looking at drug research and development spending trends, M&As,
alliances, major diseases, applications, tools, technologies, products
and services. This report suggests the future direction of the market
for biomarkers and related '-omic' or pharmacogenomic (PGx) assays or
tests used in the next-generation of drug R&D. This study sizes the
world market and growth rate of biomarkers and assays for drug R&D
spending to 2012.
Drug and biopharmaceutical developers face numerous challenges that are
being helped with emerging business and technical strategies or
approaches that utilize biomarkers to improve their chances of success.
This business area is set for strong continued growth as biomarkers and
assays in drug R&D enable new opportunities. This report estimates that
this potential multi-billion dollar market will grow at strong
double-digit rates over the five-year study period.
The study discusses ongoing regional government initiatives that are
fostering worldwide development in biomarkers and personalized medicine
opportunities. With the current group of more than 20-marketed
personalized medicines and companion tests as a model, government drug
regulators have already begun to change the labels of selected marketed
drugs to use specific companion tests to predict patient drug response.
Drug regulators are asking that drug makers use certain kidney safety
biomarker assays in drug R&D. Their goal is to streamline
commercializing new, safer, more effective drugs and co-developed
companion predictive tests by integrating biomarkers and related
pharmacogenomic (PGx), protein, imaging or other tests into the drug
R&D critical path. The study discusses how clinical trials are
undergoing important changes that integrate biomarkers and assays into
the drug R&D process to provide more meaningful information in order
for drug makers to make better product development decisions.
This study uses more than 51 figures and tables to illustrate its
useful findings. The report offers detailed information including data
tables about strategic technologies, M&As, alliances and so on.
Thirty-four selected companies are profiled with details such as
business overview, contacts, financial details and product information.
Companies Mentioned:
- 454 Life Sciences (Roche)
- Abbott Molecular
- Affymetrix
- Applied Biosystems
- Asuragen
- BD Diagnostics
- Beckman Coulter
- bioMerieux SA
- Celera
- Cepheid
- Cogenics (Clinical Data)
- Combimatrix Molecular Diagnostics
- Dako A/S
- Decision Biomarkers
- Epigenomics AG
- Expression Analysis
- Gen-Probe
- Helicos Biosciences
- Illumina
- Innogenetics NV
- LabCorp
- Luminex
- Nanosphere
- Nymox Pharmaceutical
- Orion Genomics
- Pathway Diagnostics
- Protagen AG
- QIAGEN N.V.
- Quest Diagnostics
- Roche Nimblegen
- Rules-Based Medicine
- Sequenom
- Siemens Healthcare Diag. (MDx)
- Third Wave Technologies
Report information:
http://www.researchandmarkets.com/research/b779af/biomarkers_the_fu
((Comments on this story may be sent to health@closeupmedia.com))
((Distributed on behalf of 10Meters via M2 Communications Ltd -
http://www.m2.com))
((10Meters - http://www.10meters.com))
Copyright ? 2008 Wireless News
[ Back To TMCnet.com's Homepage ]
|
INDUSTRIES
Activate Email 
Find Solutions for Enterprises, SMBs & Service Providers at the INTERNET TELEPHONY Conference and EXPO East, January 20-22, 2010. Miami, FL.
